Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950459 | 0.86 | GPR119 (0.36) | GPR119FAAHBCHEPOLBHTT | |
| SCHEMBL4145435 | 0.86 | GPR119 (0.36) | GPR119FAAHBCHEPOLBHTT | |
| SCHEMBL2490063 | 0.84 | FAAH (0.43) | GPR119FAAHBCHEPOLBHTT | |
| SCHEMBL6555078 | 0.83 | L3MBTL1 (0.35) | GPR119FAAHPOLB | |
| SCHEMBL27746941 | 0.83 | CYP2C9 (0.47) | GPR119FAAHJAK3 | |
| SCHEMBL6172065 | 0.83 | GPR119 (0.35) | GPR119FAAHBCHE | |
| SCHEMBL15208273 | 0.82 | GPR119 (0.34) | GPR119FAAHJAK3 | |
| SCHEMBL20759177 | 0.82 | CPB2 (0.39) | GPR119FAAHHTTATMMEN1 | |
| SCHEMBL31326623 | 0.82 | FAAH (0.35) | GPR119FAAHBCHEPOLBHTT | |
| SCHEMBL6771645 | 0.81 | GPR119 (0.38) | GPR119FAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | GPR119 1669/4885FAAH 4542/4885BCHE 3056/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | GPR119 1669/4885FAAH 4542/4885BCHE 3056/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | GPR119 1669/4885FAAH 4542/4885BCHE 3056/4885 |
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | ACSL5, ACSL3, ACSL6 | GPR119 282/4885FAAH 312/4885BCHE 317/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | GPR119 3084/4885FAAH 4719/4885BCHE 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.